These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 29592972)
41. An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. Prakash A; Lobo E; Kratochvil CJ; Tamura RN; Pangallo BA; Bullok KE; Quinlan T; Emslie GJ; March JS J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):48-55. PubMed ID: 22251023 [TBL] [Abstract][Full Text] [Related]
42. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. Meighen KG J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):121-7. PubMed ID: 17343560 [TBL] [Abstract][Full Text] [Related]
43. Bilateral acute angle-closure glaucoma induced by duloxetine. Mahmut A; Tunc V; Demiryurek E; Gursoy A Ideggyogy Sz; 2017 Sep; 70(9-10):358-360. PubMed ID: 29870629 [TBL] [Abstract][Full Text] [Related]
44. Duloxetine's effects in resting functional magnetic resonance imaging of first-episode, drug-naive major depressive disorder with panic disorder patients. Lai CH J Neuropsychiatry Clin Neurosci; 2011; 23(3):E10-1. PubMed ID: 21948903 [No Abstract] [Full Text] [Related]
45. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729 [TBL] [Abstract][Full Text] [Related]
46. Duloxetine and gingival bleeding: a case-report and reviews of the French and World PharmacoVigilance Databases and literature. Gicquel C; Moulis F; Chenaf C; Gouraud A; Drici M; Bondon-Guitton E; Montastruc F; Montastruc JL Eur J Clin Pharmacol; 2017 Sep; 73(9):1197-1198. PubMed ID: 28639120 [No Abstract] [Full Text] [Related]
47. Duloxetine plasma level and antidepressant response. De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837 [TBL] [Abstract][Full Text] [Related]
48. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. Li G; Wang X; Ma D Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232 [TBL] [Abstract][Full Text] [Related]
49. How Does Usage of Serotonin Noradrenaline Reuptake Inhibitors Affect Intraocular Pressure in Depression Patients? Uçan Gündüz G; Parmak Yener N; Kılınçel O; Gündüz C J Ocul Pharmacol Ther; 2018 May; 34(4):354-359. PubMed ID: 29446702 [TBL] [Abstract][Full Text] [Related]
50. Duloxetine in the treatment of elderly people with major depressive disorder. Del Casale A; Girardi P; Brugnoli R; Sani G; Di Pietro S; Brugnoli C; Caccia F; Angeletti G; Serata D; Rapinesi C; Tatarelli R; Kotzalidis GD Riv Psichiatr; 2012; 47(6):479-88. PubMed ID: 23160108 [TBL] [Abstract][Full Text] [Related]
51. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Goldstein DJ; Lu Y; Detke MJ; Wiltse C; Mallinckrodt C; Demitrack MA J Clin Psychopharmacol; 2004 Aug; 24(4):389-99. PubMed ID: 15232330 [TBL] [Abstract][Full Text] [Related]
52. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765 [TBL] [Abstract][Full Text] [Related]
53. Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study. Hellerstein DJ; Hunnicutt-Ferguson K; Stewart JW; McGrath PJ; Keller S; Peterson BS; Chen Y J Affect Disord; 2017 Mar; 210():258-264. PubMed ID: 28064115 [TBL] [Abstract][Full Text] [Related]
54. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Perahia DG; Kajdasz DK; Desaiah D; Haddad PM J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753 [TBL] [Abstract][Full Text] [Related]
55. Genome-wide association studies of placebo and duloxetine response in major depressive disorder. Maciukiewicz M; Marshe VS; Tiwari AK; Fonseka TM; Freeman N; Kennedy JL; Rotzinger S; Foster JA; Kennedy SH; Müller DJ Pharmacogenomics J; 2018 May; 18(3):406-412. PubMed ID: 28696415 [TBL] [Abstract][Full Text] [Related]
56. Duloxetine-related growth of putamen and brainstem in first-onset drug-naive major depressive disorder with panic disorder: a case series. Lai CH J Neuropsychiatry Clin Neurosci; 2011; 23(2):E40-1. PubMed ID: 21677224 [No Abstract] [Full Text] [Related]
57. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204 [TBL] [Abstract][Full Text] [Related]